<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472807</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01833-50</org_study_id>
    <nct_id>NCT03472807</nct_id>
  </id_info>
  <brief_title>EXOme Rare Cancers in Children (EXOCARE)</brief_title>
  <acronym>EXOCARE</acronym>
  <official_title>An Investigation of Susceptibility Genes for Rare Cancers in Children by Exome Sequencing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Other than high-dose radiation and previous chemotherapy, few strong risk factors have been
      identified as causes of childhood cancer. Geneticists estimate that 5 to 10% of all cancers
      diagnosed during the paediatric period occur in children born with a genetic mutation,
      increasing their lifetime risk of neoplasia. Such genetic risk is higher in children with
      congenital anomalies and specific genetic syndromes. Some germline genetic alterations are
      well known (e.g. P53 protein (P53), Neurofibromatosis type 1(NF1)), however many children
      with none of these mutations have clinical presentations that strongly suggest the
      involvement of a genetic predisposition. Comprehensive genetic testing for all such patients
      is an important factor for improving disease surveillance. Such opportunities are now
      available thanks to whole exome sequencing (WES). In oncology, an important clinical
      application of WES will be to routinely identify mutations associated with inherited cancer
      predispositions and to guide cancer risk-management decisions.

      Our project is a national translational multicenter genetics study aimed at identifying genes
      involved in paediatric cancer predisposition by WES in a very select population of children
      with both developmental delay and cancer. Our project relies on the TED register (Tumeur Et
      Développement), an initiative by the French organisation SFCE (Société Française de lutte
      contre les Cancers et les leucémies de l'Enfant et de l'Adolescent) involving 30 child cancer
      units in France. This database includes the information of more than 500 paediatric cancer
      patients with congenital abnormalities. The investigators plan to sequence the germline and
      tumour exome of 100 patients with developmental delay in a trio-design consisting of 300
      people and 100 tumours.

      The investigators believe that the ExoCaRe project will provide answers to the genetic
      origins of certain particular childhood cancers. The ExoCaRe project relies on a genetic
      study to identify genetic risk factors for rare forms of childhood cancer and aims to
      establish more personalised treatment. It is aimed at improving genetic counselling for
      families and will be fully integrated in the genetic counselling process. The information
      provided by our study will be used to improve the management approach to an initial cancer by
      clarifying the risks of other cancers in related families. The investigators hope to identify
      new germline genes predisposing to cancer that will be of interest in understanding tumour
      biology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -Primary objective : Our aim is to identify new mutations and genes involved in paediatric
      cancer predisposition associating developmental delay by WES of a sub-cohort of patients
      included in the TED database.

      -Secondary objectives :

        1. Describe inherited predisposition to cancer.

        2. Improve genetic counselling processes.

        3. Initiate clinical exome sequencing in childhood cancer treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">January 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>prospective multicenter study, not therapeutic,</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and type of germline and somatic genetic variants of pathological significance and associated with the disease.</measure>
    <time_frame>At inclusion</time_frame>
    <description>WES and RNA sequence data will be used to identify and characterise germline and somatic genetic variants of pathological significance and associated with the disease.
Descriptive statistics, such as counts and proportions of variants of pathological significance risk will be computed within each patient and family.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Related to secondary objectives (1) : Identification of biological pathways involved in childhood cancer predisposition.</measure>
    <time_frame>At inclusion</time_frame>
    <description>The deleterious mutations that the investigators will identify in genes related to childhood cancer predisposition will help to have a comprehensive framework of biological pathways involved in childhood cancer predisposition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related to secondary objectives (2) : Overall success rate.</measure>
    <time_frame>At inclusion</time_frame>
    <description>Success is defined by the combined successes of quality interpretable genomic data are generated from sequencing tumor and germline tissues, and communicating genomic test results to the primary oncologist and the patient and his/her parents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related to secondary objectives (3) : Number of clinical criteria justifying a WES.</measure>
    <time_frame>At inclusion</time_frame>
    <description>Descriptive statistics, such as counts and proportions of success by clinical presentation of the disease, by cancer types, by features of developmental delay, and, by class of age.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Predisposition, Genetic</condition>
  <condition>Cancer Childhood</condition>
  <condition>Development Delay</condition>
  <arm_group>
    <arm_group_label>Cancer patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Collection of blood sample or saliva
Collection of a tumor sample taken before the participation of the patient in study
Collection of blood sample if tumor sample is not available</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parent of cancer patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>-Collection of blood sample or saliva</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of blood sample or saliva</intervention_name>
    <description>at Inclusion</description>
    <arm_group_label>Cancer patient</arm_group_label>
    <arm_group_label>Parent of cancer patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of a tumor sample taken before the participation of the patient in study</intervention_name>
    <description>at Inclusion</description>
    <arm_group_label>Cancer patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of blood sample if tumor sample is not available</intervention_name>
    <description>at Inclusion</description>
    <arm_group_label>Cancer patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For &quot;Patient cancer&quot; :

               -  Child having developed a cancer combined with a delay of development and\or an
                  intellectual deficiency before the age of 18 years and followed for a cancer of
                  the child in one of hospital center of the Société Française de lutte contre les
                  Cancers et les leucémies de l'Enfant et de l'adolescent (SFCE)

               -  At least a parent still alive and available to make genetic analyses

          -  For &quot;Parent of cancer patient&quot; :

               -  Parent whose child meets the criteria of inclusion of &quot;Cancer patient&quot;

        Exclusion Criteria:

          -  For &quot;Cancer patient&quot; :

               -  Genetic predisposition already identified at the child

               -  Absence of histological confirmation

               -  Child died without DNA of the available germinal lineage

          -  For &quot;Parent of cancer patient&quot; :

               -  Parent whose child doesn't meets the criteria of inclusion of &quot;Cancer patient&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle PELLIER, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Angers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elsa BERARDI</last_name>
    <phone>+33 2 41 35 61 79</phone>
    <email>elberardi@chu-angers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine DEVOLDERE, MD</last_name>
      <email>devoldere.Catherine@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle PELLIER, PU-PH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center Bergonie Institut</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginie BUBIEN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie TINAT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liana-Stefania CARAUSU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine FRANCANNET, MD</last_name>
      <email>c.francannet@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence OLIVIER-FAIVRE, PU-PH</last_name>
      <email>laurence.faivre@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique PLANTAZ, PU-PH</last_name>
      <email>dplantaz@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie LEJEUNE, MD</last_name>
      <email>Sophie.lejeune@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe PIGUET, MD</last_name>
      <email>Christophe.piguet@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut of Haematology and Paediatric Oncology of Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadege CORRADINI, MD</last_name>
      <email>nadege.corradini@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delphine SIGAUDY, MD</last_name>
      <email>Sabine.sigaudy@mail.ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Carole COZE, MD</last_name>
      <email>Carole.coze@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie HAOUY, MD</last_name>
      <email>s-haouy@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno LEHEUP, MD</last_name>
      <email>b.leheup@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand ISIDOR, MD</last_name>
      <email>Bertrand.isidor@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marilyne DUPUY, MD</last_name>
      <email>poiree.m@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck BOURDEAUT, MD</last_name>
      <email>franck.bourdeaut@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Kremlin Bicetre</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène MARTELLI, PU-PH</last_name>
      <email>Helene.martelli@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine SARNACKI, PU-PH</last_name>
      <email>sabine.sarnacki@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Vincent COULOIGNER, PU-PH</last_name>
      <email>vincent.couloigner@nck.aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène BOUTROUX, MD</last_name>
      <email>Helene.boutroux@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe DENIZEAU, MD</last_name>
      <email>phildenizeau@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale SCHNEIDER, PU-PH</last_name>
      <email>Pascale.schneider@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Louis STEPHAN, MD</last_name>
      <email>j.louis.stephan@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine PAILLARD, PU-PH</last_name>
      <email>Catherine.paillard@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marion GILLIBERT-YVERT, MD</last_name>
      <email>m.gillibert-yvert@chu-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Léa GUERRINI-ROUSSEAU, MD</last_name>
      <email>Lea.guerrini-rousseau@gustaveroussy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Saint Denis de La Reunion</name>
      <address>
        <city>Saint-Denis</city>
        <country>Réunion</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathilde JEHANNE, MD</last_name>
      <email>mathilde.jehanne@chu-reunion.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Réunion</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

